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Several previous studies have demonstrated that the activity of neurotransmitters acting on ligand-gated
ion channels such as the nicotinic acetylcholine receptor (nAChR) can be altered by compounds binding to
allosteric modulatory sites. In the case of a7 nAChRs, both positive and negative allosteric modulators
(PAMs and NAMs) have been identiﬁed and have attracted considerable interest. A recent study, employing
revised structural models of the transmembrane domain of the a7 nAChR in closed and open confor-
mations, has provided support for an inter-subunit transmembrane allosteric binding site (Newcombe et al
2017). In the present study, we have performed virtual screening of the DrugBank database using phar-
macophore queries that were based on the predicted binding mode of PAMs to a7 nAChR structural
models. A total of 81 compounds were identiﬁed in the DrugBank database, of which the 25 highest-
ranked hits corresponded to one of four previously-identiﬁed therapeutic compound groups (carbonic
anhydrase inhibitors, cyclin-dependent kinase inhibitors, diuretics targeting the Naþ-Kþ-Cl- cotransporter,
and ﬂuoroquinolone antibiotics targeting DNA gyrase). The top-ranked compound from each of these four
groups (DB04763, DB08122, furosemide and peﬂoxacin, respectively) was tested for its effects on human
a7 nAChR expressed in Xenopus oocytes using two-electrode voltage-clamp electrophysiology. These
studies, conducted with wild-type, mutant and chimeric receptors, resulted in all four compounds exerting
allosteric modulatory effects. While DB04763, DB08122 and peﬂoxacin were antagonists, furosemide
potentiated ACh responses. Our ﬁndings, supported by docking studies, are consistent with these com-
pounds acting as PAMs and NAMs of the a7 nAChR via interaction with a transmembrane site.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
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r Ltd. This is an open access articlesuperfamily of pentameric ligand-gated ion channels, that also in-
cludes receptors for 5-hydroxytrptamine (5-HT), g-aminobutyric
acid (GABA) and glycine (Changeux, 2012). Seventeen nAChR sub-
units have been identiﬁed in vertebrates (a1-a10, b1- b4, g, d and ε)
that can co-assemble to generate a diverse family of pharmaco-
logically distinct nAChR subtypes (Millar and Gotti, 2009). The
human a7 nAChR has attracted interest as a target for therapeutic
drug discovery, which has arisen, in part, from evidence that a7
nAChRs may play a role in a range of neurological and psychiatric
disorders (Parri et al., 2011; Wallace and Porter, 2011). In particular,
considerable attention has focussed on studies of positive allosteric
modulators (PAMs) that are thought to bind within the receptor's
transmembrane domain (Williams et al., 2011; Chatzidaki and
Millar, 2015).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Generation of pharmacophore queries used for virtual screening. The highest
ranked clusters of binding mode solutions with previously characterised PAMs are
shownwithin the a7 nAChR transmembrane domain (A). The Ca trace of TM1-3 helices
of the principal subunit and TM2 helix of the complimentary subunit are shown for the
open (cyan) and closed (pink) conformations. Also shown are binding mode clusters
from which pharmacophore queries were generated for the open (green) and closed
(orange) conformations. From the ligands in each cluster, pharmacophore queries were
generated for the closed and open conformations (B and C, respectively). Note, only
those selected for screening are shown. Features of the pharmacophore are repre-
sented as yellow spheres (hydrophobes), green spheres (rings), red hashed spheres
(hydrogen bond acceptors) and blue hashed spheres (hydrogen bond donors). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to
the Web version of this article.)
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domain, at the interface between subunits (Changeux, 2012).
Therefore, we consider allosteric binding sites to be any binding site
that is topographically distinct from the binding site of the
endogenous agonist (the orthosteric site). In addition to PAMs,
which are allosteric ligands that potentiate agonist-evoked re-
sponses, negative allosteric modulators (NAMs) reduce agonist-
evoked responses. Homomeric a7 nAChRs are characterised by
their relatively low ACh sensitivity, rapid activation and fast
desensitisation (Couturier et al., 1990). By convention, a7 nAChR
PAMs have been classiﬁed as either ‘type I’, which have little or no
effect on desensitisation kinetics, or ‘type II’, which reduce the rate
of receptor desensitisation (Bertrand and Gopalakrishnan, 2007).
However, there is also evidence for a7-selective PAMs with inter-
mediate properties (Chatzidaki et al., 2015).
We have recently generated revised structural models of the
human a7 nAChR, based on the cryo-EM structure of the Torpedo
electric organ nAChR in its closed and open conformations, in
which an error in the transmembrane domain of the Torpedo nAChR
structure has been corrected (Newcombe et al., 2017). Previous
computer docking studies performed with our revised human a7
nAChR structural models identiﬁed an inter-subunit trans-
membrane site for allosteric modulators (Newcombe et al., 2017). In
the present study, we have extended these ﬁndings by generating
pharmacophore models to perform virtual screening of the Drug-
Bank database (Wishart et al., 2006). DrugBank is a relatively small
database, containing approximately 11,000 compounds that act on
identiﬁed drug targets, of which a relatively high proportion
(approximately 2500) are approved small molecule drugs. Our goal
in performing virtual screening with pharmacophore queries based
on a series of known a7 nAChR PAMs was to identify compounds
that may interact with the predicted allosteric transmembrane site
and may therefore act as a7 nAChR allosteric modulators.
All of the 25 highest-ranked hits identiﬁed by virtual screening
were compounds that are known to act as inhibitors of one of four
previously identiﬁed protein targets: carbonic anhydrase II (CAII),
cyclin-dependent kinase 2 (CDK2), Naþ-Kþ-Cl- cotransporter
(NKCC) and DNA gyrase (DNAG). Drugs acting on these protein
targets have been developed for use in the treatment of glaucoma
(CAII inhibitors), as anti-cancer therapies (CDC2 inhibitors), as di-
uretics (NKCC inhibitors), or as antibiotics (DNA gyrase inhibitors).
The highest ranked compounds identiﬁed by virtual screening from
each of these four drug groups (DB04763, DB08122, DB00695
[furosemide] and DB00487 [peﬂoxacin], respectively) were tested
for their effects on human a7 nAChR expressed in Xenopus oocytes.
By means of two-electrode voltage-clamp recording, all four of the
compounds were observed to have either positive or negative
modulatory effects on a7 nAChRs, either potentiating or antago-
nising responses to acetylcholine. Three of the compounds
(DB04763, DB08122 and peﬂoxacin) were found to act as NAMs of
the a7 nAChR, whereas furosemide was an a7 nAChR PAM. The
ﬁndings provide strong and direct evidence that virtual screening
can be an effective approach for the identiﬁcation of compounds
with allosteric modulatory effects on neurotransmitter receptors
such as the nAChR, even when employed with relatively small
compound libraries.
2. Materials and methods
2.1. Virtual screening
A group of 25 a7 nAChR PAMs sharing close chemical similarity
were selected (see the representative ‘TQS-family’ structure illus-
trated in Fig. 2 and also the compounds identiﬁed as ‘TQS-family’ in
the supplemental Table 1 of Newcombe et al., 2017). Thesecompounds were docked into revised structural models of the a7
nAChR transmembrane domain in both the open and closed con-
formations (Newcombe et al., 2017). Using a previously described
consensus docking protocol (Newcombe et al., 2017), the top ﬁve
solutions for each of the PAMs were clustered by RMSD with a cut-
off of 2.0 Å. The largest cluster found for each of the open and closed
docking experiments was taken to represent the active conforma-
tion of the ligand in each receptor conformation (Fig. 1). Three 3D
pharmacophore queries were created based on each of the two
clusters (one from the open form and the other from the closed
form of the a7 nAChR structural model). This was done using the
ligand model builder tool from the software package Rapid Overlay
of Chemical Structures (ROCS) (Rush et al., 2005), allowing a
maximum of six ligands to be utilized by the query generation al-
gorithm. ROCS built every variation of possible query models con-
taining between one and six ligands from the supplied binding
mode cluster, creating a gaussian volume corresponding to the
molecular shape of the overlaid ligands and assigning ‘color atoms’
at pharmacophoric points associated with hydrogen bond donors,
hydrogen bond acceptors, rings and hydrophobes in the ligands
that contributed to each of the queries that were built. Every built
query was screened against the ligands in the cluster and the three
Fig. 2. Allosteric modulators of the a7 nAChR. The general structure of the ‘TQS-family’ of compounds that were used to generate the phamacophore query is shown on the left. Four
compounds from the DrugBank database that were identiﬁed by virtual screening and selected for functional characterisation are shown on the right.
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the cluster determined by the Tanimoto Combo score (Tanimoto,
1958) for both open and closed conformation binding mode clus-
ters were selected for testing in validation screening runs (Fig. 1B
and C). Validation runs were carried out in which the pharmaco-
phore queries were screened against a database containing 42
known active a7 nAChR PAMs (Table S1) from which those PAMs
used to generate the query had been excluded) and a set of likely
non-binders, or decoys (36 decoys for each known active com-
pound), generated with decoy ﬁnder (Cereto-Massague et al.,
2012). The decoy set was generated by taking a subset of com-
pounds from the ZINC database (Irwin and Shoichet, 2005),
ensuring that the Tanimoto coefﬁcient (Tanimoto, 1958) between
the ligands in the known binder set and the decoy sets did not
surpass a threshold of 0.8. For the two sets of 3D pharmacophore
queries, the query with the largest area under the curve (AUC) in its
receiver operator characteristic (ROC) plot and with the highest
early enrichment factor was chosen to use for screening (Table S2
and Fig. S1). Next, the DrugBank database was screened to iden-
tify potential new drug-like ligands for the a7 nAChR. Two ﬁlters
were applied to the top 100 hits from each query, as determined by
the Tanimoto Combo score. The ﬁrst ﬁlter compared open and
closed conformations of each group of compounds, with only
compounds that appeared in both hit lists being selected. The
second ﬁlter was applied by selecting only compounds for which
the central nervous system multi-parameter optimisation score
was 4.0 or above. This score was calculated with an in-house script
based on the central nervous systemmulti-parameter optimisation
(Wager et al., 2010, 2016) using ChemAxon calculator plugins
(ChemAxon, Budapest, Hungary) to predict the physico-chemical
properties of the small-molecules.
2.2. Compounds and chemical synthesis
DB04763 and DB08122 were synthesised by methods that have
been described previously (Supuran et al., 1998; Bramson et al.,
2001) full details are provided in the supplementary data. Re-
agents for chemical synthesis were purchased from Fluorochem
(Hadﬁeld, UK) or Sigma-Aldrich (Gillingham, UK). All other com-
pounds, including furosemide and peﬂoxacin, were purchased from
Sigma-Aldrich (Gillingham, UK).
2.3. Plasmids and site-directed mutagenesis
Oocyte expression studies (see below) employed the human a7
nAChR subunit in plasmid pSP64GL (Broadbent et al., 2006), themouse 5-HT3AR subunit in pRK5 (Maricq et al., 1991), and a human
a7 nAChR/mouse a7/5-HT3AR chimera in pcDNA3.1 (Craig et al.,
2004). Site-directed mutagenesis was performed using the Quik-
Change mutagenesis kit (Agilent Technologies) and veriﬁed by
nucleotide sequencing (Source Bioscience). For consistency with
previous studies, the numbering of amino acids in the a7 subunit
mutated by site-directed mutagenesis is based on the predicted
signal sequence cleavage site in the mature chick a7 subunit
(Couturier et al., 1990).
2.4. Electrophysiological characterisation
Oocytes were isolated from adult female Xenopus laevis and
defolliculated by treatment with type II collagenase (2.5mg/ml;
Gibco, ThermoFisher Scientiﬁc) in calcium-free Barth's solution
containing 88mM NaCl, 2.4mM NaHCO3, 1mM KCl, 0.82mM
MgSO4, and 15mM Tris, pH 7.5, as described previously (Young
et al., 2007). Heterologous expression was achieved by cyto-
plasmic injection of in vitro transcribed cRNA. Prior to in vitro
synthesis of cRNA plasmid cDNA was linearized by restriction
enzyme digestion and puriﬁed with QIAQuik PCR puriﬁcation kit
(Qiagen). In vitro synthesis of cRNAwas performed usingmMessage
mMachine SP6 and T7 transcription kits (ThermoFisher Scientiﬁc).
Oocytes were injected with approximately 9 ng cRNA using a
Drummond variable volume microinjector. After injection, oocytes
were incubated at 14 C in a calcium-containing Barth's solution
(composition, as above, but with 0.77mM CaCl2) supplemented
with antibiotics (100 units/ml penicillin, 100 mg/ml streptomycin,
4 mg/ml kanamycin, and 50 mg/ml tetracycline). Experiments were
performed on oocytes after 3e5 days of incubation. Oocytes were
placed in a recording chamber and continuously perfused with a
modiﬁed Ringer's solution (115mM NaCl, 2.5mM KCl, 1.8mM
BaCl2, and 10mM HEPES, pH 7.3) with a ﬂow rate of approximately
15ml/min. Two-electrode voltage-clamp recordings were per-
formed using a Warner Instruments OC-725C ampliﬁer (Havard
Apparatus) with the oocyte membrane potential held at60mV, as
described previously (Young et al., 2007; Gill et al., 2012). Appli-
cation of compounds was controlled by LabChart software (AD In-
struments) using a BPS-8 solenoid valve solution exchange system
(ALA Scientiﬁc Inc). Allosteric modulators were pre-applied for 30 s
before co-application with agonist.
2.5. Statistical analysis and curve ﬁtting
Data are presented as means± SEM of at least three indepen-
dent experiments, that were conducted on separate oocytes. For
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an unpaired one-way analysis of variance (ANOVA). Post-hoc
analysis was performed with a Tukey multiple comparison test.
For individual comparisons, statistical signiﬁcance was determined
using unpaired t-tests. In order to produce concentration-response
curves for wild-type and mutant a7 receptors, current response
data was normalised and ﬁtted to the sigmoidal function:
I=Imax ¼ 1
1þ 10

log

EC50
½agonist

nH

where I is the current and Imax is the maximum current. EC50 is the
concentration of agonist that evokes 50% of the maximum current
and nH is the Hill coefﬁcient. Inhibition curves were ﬁtted using the
following equation, where IC50 is the concentration of the antago-
nist that is required to inhibit the maximum response by 50%:
I=Imax ¼ 1"
1þ 10

log

½antagonist
IC50

nH
#
3. Results
3.1. Virtual screening
Virtual screening of the DrugBank database (Wishart et al.,
2006) was performed with the aim of identifying novel allosteric
modulators of the human a7 nAChR. Six pharmacophore queries
(Fig. 1) were generated, based on the predicted bound conforma-
tion within the open and closed structural models of the a7 nAChR
(Newcombe et al., 2017) of a series of 25 compounds that are
known to have PAM activity on the a7 nAChR (see the represen-
tative ‘TQS-family’ structure illustrated in Fig. 2 and also the com-
pounds identiﬁed as ‘TQS-family’ in the supplemental Table 1 of
Newcombe et al., 2017). Validation runs, in which the pharmaco-
phore queries were screened against 42 known active a7 nAChR
PAMs, suggested that they were of high quality, as indicated by AUC
values from ROC plots of 0.949 or greater for all queries (Table S2).
For both the closed and open queries generated, query 2 had the
best validation scores, with the highest AUC (0.971 and 0.967
respectively) as well as the highest early enrichment across 0.5%,1%
and 2% thresholds (Table S2 and Fig. S1). The DrugBank database
(Wishart et al., 2006) was screened with the selected pharmaco-
phore queries, after applying two ﬁlters (see Materials and
Methods) to the top 100 hits from each query, 81 compounds were
identiﬁed (Table S3).
3.2. Selection of compounds for functional characterisation
From the 81 compounds identiﬁed by virtual screening of the
DrugBank database, four were selected for detailed functional
characterisation on a7 nAChRs expressed in Xenopus oocytes
(DB00487 [peﬂoxacin], DB00695 [furosemide], DB04763 and
DB08122; Fig. 2). These were the highest-ranked members of the
four classes of compounds that were represented in the 25 top-
ranked virtual screening hits (Table S3). DB04763, a CAII inhibitor
(Scozzafava et al., 2000), is the top-ranked compound identiﬁed by
virtual screening. It is one of 22 CAII inhibitors in the 25 top-ranked
compounds and also one of 36 such compounds in the 81 total hits
(Table S3). DB08122 is the 3rd-ranked compound identiﬁed by
virtual screening and is a CDK2 inhibitor (Bramson et al., 2001). It is
the only example of a CDK2 inhibitor in the 25 top-ranked hits butit is one of seven CDK2 inhibitors within the 81 total hits (Table S3).
Furosemide (DB00695) is the 6th-ranked hit from virtual screening
and is a diuretic that acts on the Naþ-Kþ-Cl- cotransporter. No other
compounds with a similar known mechanism of action were
identiﬁed amongst the 81 virtual screening hits. Peﬂoxacin
(DB00487), a ﬂuroquinolone antibiotic (Wolfson and Hooper,1989),
is the 22nd-ranked hit and is the only example of this type of
compound in the 25 top-ranked hits but it is one of 13 such com-
pounds within the 81 total hits (Table S3). Overlays of the selected
compounds with the original pharmacophore queries demon-
strates their close match to the shape of the ‘TQS-family’ of PAMs
(Fig. S2).
3.3. Functional characterisation
Selected compounds identiﬁed by virtual screening of the
DrugBank database were tested on the human a7 nAChR expressed
in Xenopus oocytes by two-electrode voltage-clamp recording.
Initial studies focussed on the diuretic furosemide (ranked 6th;
Table S3), which is the highest ranked compound identiﬁed by
virtual screening that is available commercially. As has been re-
ported previously (Couturier et al., 1990), application of ACh to a7
nAChRs resulted in rapidly desensitising inward currents (Fig. 3A).
Furosemide (1mM) had no effect on a7 nAChRswhen applied alone
but when tested under our standard protocol for PAMs (pre-
application followed by co-application with ACh) this resulted in a
dose-dependent potentiation of agonist-evoked responses (Fig. 3B).
In contrast, in the absence of pre-application, no signiﬁcant
potentiation of ACh responses was observed (Fig. S3). When a range
of concentrations of furosemide were co-applied with an EC20
concentration of ACh (50 mM), agonist-evoked responses were
potentiated with an EC50 value of 0.2± 0.04mM (n¼ 3) (Fig. 3C). At
high concentrations of furosemide (1mM), the maximum level of
potentiation of ACh responses was 1.6± 0.1 fold (Fig. 3B), similar to
that reported previously for type I PAMs that have chemical
structures similar to the compounds used to generate the phar-
macophore model (Gill-Thind et al., 2015).
Furosemide was also tested on another closely related ligand-
gated ion channel, the homomeric mouse 5-HT3AR (Maricq et al.,
1991). As had been observed with the a7 nAChR, furosemide had
no agonist effect when applied alone to the 5-HT3AR. When tested
on maximal agonist concentrations (3mM ACh for a7 and a7/5-
HT3AR chimera; 30 mM 5-HT for 5-HT3AR), in contrast to the clear
potentiating effect observed with furosemide on the human a7
nAChR, furosemide (1mM) had only a veryweak potentiating effect
(108 ± 2%, n¼ 4, P¼ 0.027) on the mouse 5-HT3AR (Fig. 4). This is
signiﬁcantly less than the PAM effect observed in parallel experi-
ments conducted with human a7 nAChR (149± 6%, n¼ 14;
P¼ 0.002). If furosemide is acting at a transmembrane site, we
would predict that it might have a similarly low potentiating effect
on receptors generated by expression of a previously described
chimera (a7/5-HT3AR) containing the extracellular domain of the
human a7 nAChR fused to the transmembrane and C-terminal
domain of the mouse 5-HT3AR (Craig et al., 2004). As predicted,
furosemide exerted a very low PAM effect on the a7/5-HT3AR
chimera (108 ± 2%) that was signiﬁcantly less than its effect on a7
nAChR (P¼ 0.004) but was not signiﬁcantly different from its effect
on the 5-HT3AR (P¼ 0.963; Fig. 4). The experiment was also
repeated with submaximal (EC50) agonist concentrations (100 mM
ACh for a7 and a7/5-HT3AR chimera; 1 mM 5-HT for 5-HT3AR). As
previously, in contrast to clear potentiation of a7 nAChRs (136± 7%
n¼ 6), furosemide (1mM) was observed to have no signiﬁcant ef-
fect on 5-HT3AR (93.9± 3.7% n¼ 9, P¼ 0.137) or on the a7/5-HT3AR
chimera (98.2± 3.4% n¼ 8, P¼ 0.619). Thus, studies conductedwith
maximal and submaximal agonist concentrations are consistent
Fig. 3. Functional characterisation of furosemide on the a7 nAChR. A) Representative
traces illustrating responses of a7 nAChRs to ACh (100 mM; left), together with ACh
responses from the same oocyte after pre- and co-application of furosemide (1mM;
middle). Also shown (right) is a response to ACh (100 mM) following wash. The vertical
scale bar corresponds to 200 nA and the horizontal scale bars to 2.5 s. B) Responses
with varying concentrations of ACh in the absence (open circles) and presence (closed
circles) of a ﬁxed concentration (1mM) of furosemide. Data are normalised to the
maximum ACh response and are means ± SEM of three independent experiments. C)
Concentration-response data illustrating potentiation of responses to ACh (50 mM) by
varying concentrations of furosemide. Data are normalised to the EC20 concentration of
ACh (50 mM) and are means± SEM of three independent experiments.
Fig. 4. Functional characterisation of furosemide on a7 nAChR, 5-HT3AR and an a7/5-
HT3AR chimera. The effect of furosemide was examined with either a maximal or an
EC50 concentration of agonist (A and B, respectively). A) Furosemide (1mM) was pre-
and co-applied with a maximal concentration of agonist (3mM ACh for a7 and a7/5-
HT3AR chimera; 30 mM 5-HT for 5-HT3AR). B) Furosemide (1mM) was pre and co-
applied with an EC50 concentration of agonist (100 mM ACh for a7 and a7/5-HT3AR
chimera; 1 mM 5-HT for 5-HT3AR). In both cases potentiation of the a7 nAChR was
signiﬁcantly greater than potentiation with the 5-HT3AR and with the a7/5-HT3A
chimera. Data are means ± SEM (n ¼ 4e8). Signiﬁcant differences are indicated
(**P < 0.01, ***P< 0.001).
C.L.C. Smelt et al. / Neuropharmacology 139 (2018) 194e204198with furosemide potentiating the a7 nAChR by acting at a site other
than the extracellular domain.
Given that the pharmacophores used for virtual screening were
based on allosteric modulators that are predicted to bind in the a7
nAChR transmembrane region, the simplest explanation for the
PAM effects observed with furosemide is that it acts at a similar
transmembrane site. Previous studies have revealed that the effects
of known a7 PAMs can be altered by single point mutations in the
transmembrane domain (Young et al., 2008; Gill et al., 2011;Chatzidaki et al., 2015). Docking studies with furosemide into our
revised structural model of the a7 nAChR (Newcombe et al., 2017)
identiﬁed three amino acids in close proximity (within 3.5 Å) to the
predicted furosemide binding site within the inter-subunit trans-
membrane region (L247, S248 and T288; Fig. 5), which are pre-
dicted to form hydrogen bonds (T288) or have hydrophobic
interactions (L247 and S248) with the ligand. Each of these amino
acids were individually mutated to alanine (L247A, S248A and
T288A) and the effect of the mutations examined by expression of
mutated a7 nAChRs in Xenopus oocytes. Two of the mutations
(S248A and T288A) had no signiﬁcant effect on sensitivity to the
Fig. 5. Inﬂuence of a7 nAChR mutations on the allosteric modulatory effect of furosemide. The docked position of furosemide is shown in the closed (A) and open (B) structural
model of the a7 nAChR transmembrane region. The TM1-3 helices of the principal subunit (khaki) and TM2 and TM3 helices of the complimentary subunit (green) are shown.
Amino acids examined by site-directed mutagenesis are indicated. C) ACh dose-response curves determined with wild-type a7 nAChR (dashed line) and with a7 nAChRs containing
single point mutations S222M, L247A, S248A, M260L and T288A. Data are means of at least three independent experiments. D) Bar chart illustrating the inﬂuence of furosemide
(1mM) on responses to an EC50 concentration of ACh (10 mM for L247A and 100 mM for wild-type and all other mutated receptors). Data are normalised to the response observed in
the same oocyte in the absence of furosemide. Data are means ± SEM of at least three independent experiments. Signiﬁcant differences from wild-type are indicated (*P < 0.05,
**P< 0.01). In addition, signiﬁcant differences from agonist responses in the absence of furosemide are indicated (#P< 0.05, ##P< 0.01). (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the Web version of this article.)
C.L.C. Smelt et al. / Neuropharmacology 139 (2018) 194e204 199orthosteric agonist ACh (Fig. 5C). However, L247A caused a reduc-
tion in the rate of agonist-evoked desensitisation and a leftward
shift in the dose-response curve for ACh (EC50¼ 9.5± 0.4 mM, n¼ 3,
P¼ 0.001; Fig. 5C), as has been reported previously for other mu-
tations at this position (Revah et al., 1991). All three mutations
(L247A, S248A and T288A) abolished potentiation by furosemide
(1mM) of agonist-evoked responses (Fig. 5D). The ACh-evoked
responses in the presence of furosemide (1mM) on a7 nAChRs
containing the L247A, S248A and T288A mutations were notsigniﬁcantly different from control responses (99.9± 4.3% n¼ 4,
P¼ 0.980; 102± 5.6% n¼ 6, P¼ 0.712; and 99.2± 1.2% n¼ 6,
P¼ 0.568, respectively). These changes in response were signiﬁ-
cantly different in comparison to ACh-evoked responses on the
wild-type a7 nAChR in the presence of furosemide (1mM)
(P¼ 0.012, 0.011 and 0.006, respectively). In addition, we examined
two other a7 nAChR transmembrane mutations (S222M and
M260L) that have been shown previously to inﬂuence allosteric
modulation (Young et al., 2008; Chatzidaki et al., 2015; Newcombe
C.L.C. Smelt et al. / Neuropharmacology 139 (2018) 194e204200et al., 2017). Neither mutation had a signiﬁcant effect on sensitivity
to ACh (Fig. 5C) but both altered sensitivity to furosemide (Fig. 5D).
Mutation S222M caused a signiﬁcant (P¼ 0.0018) increase in
potentiation of an EC50 concentration of ACh by furosemide (1mM)
compared with wild-type receptor (potentiation of 244± 25%,
n¼ 4, compared with 136± 7% for wild-type, n¼ 6; Fig. 5D). Mu-
tation M260L converted furosemide into an antagonist. Agonist-
evoked responses in the presence of furosemide (1mM) were
63± 8% (n¼ 5) of the control response, in comparison to 136± 7%
(n¼ 6) for the wild-type receptor (Fig. 5D).
Three other compounds identiﬁed by virtual screening of the
DrugBank database were also tested on a7 nAChRs expressed in
Xenopus oocytes (DB04763, DB08122 and peﬂoxacin), correspond-
ing to the top ranked CAII inhibitor, CDK2 inhibitor and ﬂuo-
roquinolone antibiotic hits, respectively. None of the three
compounds had any signiﬁcant effect when applied alone to a7
nAChRs but all signiﬁcantly inhibited agonist-evoked responses in a
dose-dependent manner when co-applied with ACh (Fig. 6AeD).
Note, although a standard protocol was used for all of the data that
is presented (whereby compounds were pre-applied for 30s, fol-
lowed by co-application), in contrast to the modulatory effect
observed with furosemide which required pre-application, signiﬁ-
cant antagonism was observed with all three compounds in the
absence of pre-application (Fig. S3). At high concentrations (1mM)
DB04763 caused an almost complete block of responses to an EC50
concentration of ACh (3.4± 0.9% of the control response, n¼ 3,
P¼ 0.0001). In contrast, high concentrations (1mM) of DB08122
and peﬂoxacin caused a partial block of responses to an EC50 con-
centration of ACh (60.6± 1.2%, n¼ 3, P¼ 0.0001 and 25.9± 2.1%,
n¼ 5, P¼ 0.0001, of the control response respectively) (Fig. 6D).
This level of antagonism is similar to that reported previously for
NAMs that have chemical structures similar to the compounds used
to generate the pharmacophore model (Gill-Thind et al., 2015).
When a range of concentrations of DB04763, DB08122 and
peﬂoxacin were co-applied with an EC50 concentration of ACh
(100 mM), agonist-evoked responses were inhibited with IC50
values of 46.4± 2.2 mM (n¼ 3),1.7± 0.3mM (n¼ 3) and
388± 2.1 mM (n¼ 5), respectively (Fig. 6D). When each of the three
compounds (at 100 mM) was co-applied with a range of ACh con-
centrations, the antagonism was found to be non-surmountable
(Fig. 6E), which suggests a non-competitive mechanism of action
and is consistent with the compounds acting as NAMs.
As described above for furosemide, the inﬂuence of DB04763,
DB08122 and peﬂoxacin (all at 100 mM) were examined on re-
sponses evoked by a maximal agonist concentration on a7 nAChRs,
the 5-HT3ARs and the a7/5-HT3AR chimera (Fig. 7). DB04763
inhibited responses on a7 nAChRs to 20.0± 1.3% (n¼ 6), DB08122
to 76.0± 4.8% (n¼ 6) and peﬂoxacin to 57.7± 4.7% (n¼ 6). In
contrast DB08122 and peﬂoxacin did not cause signiﬁcant inhibi-
tion on responses on 5-HT3ARs and responses were inhibited toFig. 6. Functional characterisation of DB04763, DB08122 and peﬂoxacin on the a7
nAChR. A-C) Representative traces, from oocytes expressing the a7 nAChR, in response
to ACh (100 mM; left), together with an ACh response from the same oocyte after pre-
and co-application of test compound (1mM; middle). Also shown are responses to ACh
(100 mM) after a 2min wash (right). Data are shown for DB04763 (A), DB08122 (B) and
peﬂoxacin (C), all at 1mM. Vertical scale bars correspond to 500 nA and horizontal
scale bars correspond to 5 s. D) Concentration-response data illustrating antagonism of
responses to ACh (100 mM) by varying concentrations of DB04763 (ﬁlled circles),
DB08122 (open circles) and peﬂoxacin (crossed circles). Data are normalised to the
response to an EC50 concentration of ACh (100 mM) and are means ± SEM of three
independent experiments. E) Responses to varying concentrations of ACh in the
presence of a ﬁxed concentration (100 mM) of DB04763 (ﬁlled circles), DB08122 (open
circles) and peﬂoxacin (crossed circles). Data are normalised to the response to a
maximum concentration of ACh (3mM) and are means± SEM of 3e4 independent
experiments.
Fig. 7. Functional characterisation of DB04763, DB08122 and peﬂoxacin on the 5-
HT3AR and a7/5-HT3AR chimera. The effects of DB04763 (A), DB08122 (B) and
peﬂoxacin (C), were examined by pre- and co-application (100 mM) with a maximal
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When tested on the a7/5-HT3AR chimera the effects of all three
compounds were signiﬁcantly different to that observed on a7
nAChRs (DB04763, P< 0.0001; DB08122, P¼ 0.0012 and peﬂoxacin,
P< 0.0001) and not signiﬁcantly different to their effects on 5-
HT3ARs (Fig. 7). These ﬁndings are consistent with these antago-
nists acting at a site other than the extracellular domain. These
experiments were also repeated to examine the effects of the
compounds on responses to a submaximal (EC50) concentration of
agonist. For all compounds tested, higher levels of inhibition were
observed with 5-HT3ARs than had been the case with maximal
agonist concentrations. Because relatively high levels of inhibition
were observed on both a7 nAChRs and on 5-HT3ARs, it was felt that
studies with the a7/5-HT3AR chimera would not be helpful in
identifying the receptor domain through which the antagonist ef-
fect was occurring. However the data obtained with maximal
concentrations of agonist are consistent with the three compounds
exerting an inhibitory effect on a7 nAChRs via a transmembrane
site.
In addition, the three antagonists (DB04763, DB08122 and
peﬂoxacin) were examined on a7 nAChRs containing the series of
single transmembrane mutations that had been examined with
furosemide (S222M, L247A, S248A M260L and T288A) (Fig. 8). The
effect of the compounds (100 mM) was examined on responses to a
submaximal (EC50) concentration of ACh. In comparison to the ef-
fects of the compounds on wild-type receptors, signiﬁcant differ-
ences in the levels of antagonism were observed with DB04763 on
two of themutated receptors (L247A andM260L), with DB08122 on
four of the mutated receptors (S222M, M260L, T288A and S248A)
and with peﬂoxacin on three of the mutated receptors (L247A,
T288A and S248A) (Fig. 8). In comparison to normalised responses
observed on wild-type receptors in the presence of DB04763
(20.1± 3.1%, n¼ 6), responses were signiﬁcantly larger on L247A
(52.4± 0.8% n¼ 6, P< 0.0001) and on M260L (30.1± 2.4% n¼ 8,
P¼ 0.0243). In comparison to normalised responses observed on
wild-type receptors in the presence of DB08122 (90.6± 1.8%, n¼ 6),
responses were signiﬁcantly reduced on S222M (77.2± 3.7% n¼ 6,
P¼ 0.0087) and on T288A (65.0± 1.2% n¼ 6, P< 0.0001). In
contrast, antagonism by DB08122 was abolished on M260L
(101± 3.1% n¼ 6, P¼ 0.0112) and on S248A (99.6± 1.6% n¼ 6,
P¼ 0.039). In comparison to normalised responses observed on
wild-type receptors in the presence of peﬂoxacin (79.9± 1.6%,
n¼ 7), responses were signiﬁcantly smaller on L247A (72.7± 0.7%,
n¼ 6, P¼ 0.0025), S248A (71.8± 3.5%, n¼ 5, P¼ 0.0458) and T288A
(45.9± 5.8%, n¼ 7, P¼ 0.0001) (Fig. 8).
4. Discussion
The success of our virtual screening approach, as illustrated by
evidence that all four of the compounds tested in functional assays
displayed allosteric modulatory activity on a7 nAChRs, provides
further support for our revised structural models of the a7 nAChR
(Newcombe et al., 2017). The revised a7 models were based upon
the electron diffraction structures of the Torpedo nAChR (Unwin,
2005; Unwin and Fujiyoshi, 2012) after correcting what had been
identiﬁed previously as an error in the assignment of amino acids
within the transmembrane region of the Torpedo nAChR structure
(Corringer et al., 2010; Hibbs and Gouaux, 2011; Mnatsakanyan and
Jansen, 2013). As discussed previously (Newcombe et al., 2017), anconcentration of agonist (3mM ACh for a7 and a7/5-HT3AR chimera; 30 mM 5-HT for 5-
HT3AR) on the a7 nAChR, 5-HT3AR and a7/5-HT3AR chimera. All three of the com-
pounds inhibited the 5-HT3AR and a7/5-HT3AR chimera to a signiﬁcantly lower extent
than was observed with the a7 nAChR. Data are means ± SEM (n ¼ 4e6). Signiﬁcant
differences are indicated (**P < 0.01, ***P< 0.001).
Fig. 8. Inﬂuence of a7 nAChR mutations on the allosteric modulatory effect of
DB04763, DB08122 and peﬂoxacin. Data are shown for DB04763 (A), DB08122 (B) and
peﬂoxacin (C). Bar charts illustrate the inﬂuence of the compounds (100 mM) on
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from receptors embedded in a lipid membrane), rather than any of
the more recently determined structures of detergent-solubilised
receptors would avoid concerns that the removal of membrane
lipids during protein puriﬁcation might inﬂuence the overall
transmembrane structure. In addition, it avoided the possibility
that the close packing of receptors in three-dimensional crystals
might alter protein conformation. A further advantage of using the
corrected Torpedo nAChR structures as a starting point for gener-
ating a7 structural models is that Torpedo nAChR structures are
available that correspond to both an open and closed state (Unwin,
2005; Unwin and Fujiyoshi, 2012). Although PAMs can be viewed as
stabilizing the open conformation of the receptor (and NAMs the
closed conformation), our initial docking studies were performed
with both open and closed conformations to avoid a bias and this
may have accounted for our identiﬁcation by virtual screening of
both PAMs and NAMs.
Several previous reports of virtual screening aimed at the
identiﬁcation of nicotinic ligands have been based on structural
models of nAChR extracellular domains (Peng et al., 2010;
Mahasenan et al., 2011; Chen et al., 2013; Kombo and Bencherif,
2013; Zheng et al., 2016; Lefﬂer et al., 2017) or on the structure of
the acetylcholine binding protein, which is homologous to the
nAChR extracellular domain (Babakhani et al., 2009; Ulens et al.,
2009; Utsintong et al., 2009, 2012). In contrast, our aim was to
perform virtual screening with pharmacophores focusing on the
transmembrane domain of the human a7 nAChRs and our recent
revised models (Newcombe et al., 2017). Remarkably, all four of the
compounds that we have examined in functional assays exhibit
allosteric modulatory effects when tested on expressed a7 nAChRs.
These compounds represent four functional classes (CAII inhibitors,
CDK2 inhibitors, diuretics targeting the Naþ-Kþ-Cl- cotransporter
and ﬂuoroquinolone antibiotics) and were selected because they
represent all compound classes within the top 25 virtual screening
hits and are also representative of 58 of the total 81 compounds
identiﬁed.
The highest ranked hit from virtual screening that was available
commercially for purchase was furosemide (the 6th-ranked hit;
Table S3), a loop diuretic that acts on the Naþ-Kþ-2Cl- cotransporter
(O'Grady et al., 1987). Interestingly, in a study conducted almost 30
years ago it was reported that furosemide increased contraction of
rat urinary bladder by potentiating the action of acetylcholine, and
that this effect could be blocked by the nicotinic receptor antago-
nist hexamethonium (Okpukpara and Akah, 1989). In addition,
there is more recent evidence indicating that functional a7 nAChRs
are expressed in rat urinary bladder epithelial cells (Beckel et al.,
2006). Consequently, our ﬁnding that furosemide acts as a PAM
of a7 nAChRs provides a plausible explanation for the previously
reported effects of furosemide in potentiating acetylcholine-
induced bladder contraction (Okpukpara and Akah, 1989). Previ-
ous studies have also demonstrated that furosemide acts as an
antagonist of GABAARs (Korpi et al., 1995), which are also members
of the superfamily of pentameric ligand-gated ion channels. It has
also been suggested that furosemide interacts with GABAAR via a
transmembrane binding site (Thompson et al., 1999), a conclusion
that is consistent with the ﬁndings in the present study concerning
the a7 nAChR. Furosemide potentiated agonist responses in a7
nAChRs but did not alter the rate of agonist-induced desensitisationresponses to an EC50 concentration of ACh (10 mM for L247A and 100 mM for wild-type
and all other mutated receptors). Data are normalised to the response observed in the
same oocyte in the absence of the compounds. Data are means ± SEM of at least three
independent experiments. Signiﬁcant differences from wild-type are indicated
(*P < 0.05, **P < 0.01, ***P< 0.001). In addition, signiﬁcant differences from agonist
responses in the absence of the compounds are indicated (##P< 0.01, ###P< 0.001).
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(Bertrand and Gopalakrishnan, 2007).
As described above, the pharmacophore queries used for virtual
screening (Newcombe et al., 2017) were based on PAMs that are
predicted to bind in the a7 nAChR transmembrane domain (Gill
et al., 2011, 2012; Chatzidaki et al., 2015; Gill-Thind et al., 2015).
This suggests that furosemide may exert its PAM effects by binding
to a similar transmembrane site. Evidence supporting this conclu-
sion has been provided by studies conducted with 5-HT3AR and an
a7/5-HT3AR chimera containing the extracellular domain of the a7
subunit fused to the transmembrane and C-terminal domain of the
5-HT3AR. Furosemide displayed a signiﬁcantly lower level of
potentiation on both the 5-HT3AR and on the chimera (Fig. 4). Re-
sults of docking simulations of furosemide with our revised a7
structural models are also consistent with furosemide binding to an
inter-subunit transmembrane site (Fig. 5). On the basis of these
docking studies, three transmembrane amino acids (L247, S248 and
T288) were identiﬁed as being in close proximity to the predicted
binding site of furosemide (Fig. 5AeB). Point mutations introduced
at all three of these positions abolished potentiation by furosemide
(Fig. 5D), which is consistent with the possibility of altering the
interaction of furosemide with a transmembrane binding site. The
effects of furosemide were also altered by two additional trans-
membrane mutations (S222M and M260L), both of which have
been reported previously to alter the properties of PAMs that are
thought to interact with the transmembrane region (Young et al.,
2008; Chatzidaki et al., 2015; Newcombe et al., 2017). Although
these two transmembrane mutations are located further from the
predicted transmembrane allosteric binding site, it seems reason-
able to think that a transmembrane mutation may exert effects on
allosteric modulators through a longer-range alteration in trans-
membrane structure or alter an allosteric gating mechanism.
The other three compounds examined (DB04763, DB08122 and
peﬂoxacin) acted as antagonists of a7 nAChR (Fig. 6). In all three
cases the antagonism was non-surmountable (Fig. 6E), which in-
dicates a non-competitive mechanism of action. This is consistent
with the conclusion that they are acting as a7 nAChR NAMs. As was
the case with furosemide, the extent of modulation observed with
the three NAMs was altered signiﬁcantly by multiple trans-
membrane mutations (Fig. 8). Similarly, as with furosemide, evi-
dence from studies conducted with an a7/5-HT3AR chimera are
consistent with the three antagonists acting via a transmembrane
binding site. In all cases antagonism was either abolished or
signiﬁcantly reduced on the a7/5-HT3AR chimera (Fig. 7). Previous
studies have demonstrated that even very small changes in com-
pound structure, for example changes in the extent of methyl-
substitution of a single aromatic ring, can convert a7 nAChR
PAMs into NAMs (Gill-Thind et al., 2015). Therefore, it is not un-
expected that virtual screening conducted with pharmacophore
queries derived from a7 nAChR PAMs would identify compounds
acting as NAMs.
We are unaware of any previous evidence indicating that in-
hibitors of CAII (such as DB04763) or of CDK2 (such as DB08122)
can exert allosteric modulatory effects on nAChRs. Peﬂoxacin is a
member of the quinolone class of broad-spectrum antibiotics that
interfere with bacterial DNA replication via action on DNA gyrase
(Aldred et al., 2014). Interestingly, previous studies have indicated
that quinolone antibiotics can act as antagonists of GABAARs and it
has been suggested that this may explain some of the adverse CNS
side effects associated with quinolone antibiotics (Halliwell et al.,
1993).
For some of the compounds examined (furosemide and
DB04763) pre-application prior to co-application with agonist was
required to see maximal modulatory effects (Fig. S3). It is possible
that this may reﬂect restricted access and slower equilibration at atransmembrane binding site compared to agonist binding to the
extracellular orthosteric site. Indeed a slower rate of activation is
observed for allosteric agonists that are thought to interact with a
transmembrane binding site compared to orthosteric agonists (Gill
et al., 2011, 2012; Chatzidaki et al., 2015; Gill-Thind et al., 2015).
In summary, we have performed virtual screening of the
DrugBank database with pharmacophore models that were
generated from the structures of PAMs that have been shown
previously to interact with an inter-subunit transmembrane site of
the a7 nAChR. Four compounds, representative of the highest-
ranking hits from the virtual screen, were tested experimentally
by electrophysiology andmutagenesis studies and all were found to
display properties on a7 nAChR consistent with them acting as
allosteric modulators.
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